
Opinion|Videos|March 18, 2024
Current Front-Line Targeted Treatments in Ph+ ALL
Elias Jabbour, MD, provides an overview of the history of targeted agents and the use of tyrosine kinase inhibitors (TKIs) in the treatment of Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL).
Advertisement
Episodes in this series

Newsletter
Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on AJMC
1
Barriers to Treatment in Pediatric Myasthenia Gravis: Jonathan Strober, MD
2
Emerging Breakthroughs in Neurodegenerative Disease Treatments: Kavita Nair, PhD, FAAN
3
Defining Relapse and Switching Therapies in Multiple Myeloma
4
Evidence for GLP-1 Therapy in MASH
5














































